AI model can track Lutathera response on PET/CT

Researchers led by Amy Weisman, PhD, a medical physicist at the University of Wisconsin-Madison and lead project scientist for software developer AIQ Solutions, trained a fully automated software application to evaluate lesion response over the course of neuroendocrine cancer treatment with Lutetium-177 DOTATATE (Lutathera, Novartis). They found that the software identified hundreds of lesions that had completely resolved as well as hundreds of new lesions.

Lutathera was approved in 2018 for treating patients with advanced neuroendocrine cancer. The drug prolongs survival, yet many…